DGAP-News: WILEX AG: WILEX Inc. signs distribution agreement with Immundiagnostik AG for D-A-CH region
(firmenpresse) - DGAP-News: WILEX AG / Key word(s): Alliance
WILEX AG: WILEX Inc. signs distribution agreement with Immundiagnostik
AG for D-A-CH region
12.12.2012 / 07:11
---------------------------------------------------------------------
PRESS RELEASE
WILEX Inc. signs distribution agreement with Immundiagnostik AG for D-A-CH
region
Munich / Bensheim, Germany, 12 December 2012. WILEX AG (ISIN DE0006614720 /
WL6 / Frankfurt Stock Exchange) today announced that its US subsidiary
WILEX Inc., Cambridge, MA, USA, has entered into an exclusive distributor
agreement with Immundiagnostik AG, Bensheim, Germany for the
commercialisation of the serum HER-2/neu and CA IX ELISA tests in Germany,
Austria and Switzerland (D-A-CH region). Immundiagnostik AG is specialised
in the development and production of innovative immunoassays and other
analytical detection methods. Financial terms of the agreement were not
disclosed.
WILEX Inc. specialises in serum based oncoprotein diagnostics and offers
various biomarker tests under the brand name Oncogene Science. The serum
HER-2/neu test is the only FDA-cleared IVD ELISA that measures the serum
HER-2/neu level for the management and monitoring of patients with
metastatic breast cancer (MBC). HER-2 (Human Epidermal Growth Factor
Receptor 2) is a protein found on some types of cancer cells, especially
breast cancer cells. MBC patients who overexpress the HER-2/neu protein
tend to have a worse prognosis and a more aggressive disease. WILEX's serum
HER-2/neu ELISA test is used to monitor breast cancer patients on a variety
of therapies, including HER-2/neu-targeted therapies. The test measures
changes in the HER-2 status with increasing serum levels of HER-2/neu being
reflective of cancer progression while decreasing serum levels being
reflective of therapy response.
The CA IX ELISA test is used for the quantitative detection of the
circulating form of the CA IX (Carbonic Anhydrase IX) in serum and plasma.
The protein CA IX is overexpressed in many types of cancer and its
expression is strongly induced by hypoxia. In a variety of human cancers,
tumour hypoxia is associated with an increased incidence of metastases.
Professor Olaf G. Wilhelm, CEO of WILEX Inc. and WILEX AG, comments: 'With
Immundiagnostik AG we have found a competent and experienced partner with a
broad product and service portfolio in the field of in vitro diagnostics.
Their extensive network and cooperation with universities and international
research institutions as well as with laboratory medicine units offers the
right framework for the distribution of our serum HER-2/neu and CA IX ELISA
tests in the important German speaking market.'
'We look forward to working with WILEX. Both serum based oncoprotein ELISA
tests ideally complement our portfolio and provide the opportunity to
further expand into the field of companion diagnostics. The serum HER-2/neu
test is the most frequently used ELISA based assay in clinical trials
worldwide, which offers laboratories an efficient and reliable possibility
for the measurement of HER-2/neu in serum with no need for further
equipment', Dr Franz Paul Armbruster, CEO of Immundiagnostik AG, said.
About Immundiagnostik AG
Immundiagnostik AG, founded in 1986, is a globally operating diagnostics
company represented in over 60 countries. The company focuses on the
development and production of innovative assays for medical routineand
research. Immundiagnostik's core competence lies in antigen/antibody-based
analytical detection methods such as immunoassays (ELISA, EIA) and
immunologically-based HPLC and LC-MS/MS. Immundiagnostik's mission is to
provide effective tools for prevention, differential diagnosis and therapy
monitoring in the areas of gastroenterology, cardiovascular diseases,
disorders of the skeletal system and oxidative stress. The product
portfolio is completed by a broad range of antibodies and antigens
developed in-house. Multiple collaborations with the pharmaceutical
industry and a tight network with scientific organisations are the basis
for a successful product development with new parameters. The comprehensive
range of products is continuously refuelled by a rich pipeline of
proprietary developments. With a headcount of more than 60 employees,
Immundiagnostik's headquarter is located in Bensheim, south-western
Germany. For more information, please visit the website
www.immundiagnostik.com.
About WILEX Inc.
WILEX Inc. is a wholly owned US subsidiary of WILEX AG, Munich, Germany and
manufactures, markets and sells diagnostic tests in oncology under the
brand name Oncogene Science. The product portfolio includes Enzyme-linked
ImmunoSorbent Assays (ELISA) and immunohistochemical (IHC) assays. With the
aim of supporting treatment regimens for cancer patients worldwide WILEX
Inc. offers biomarker tests for measuring oncogenes, growth factor
receptors (HER-2/neu, EGFr), proteases and protease inhibitors (uPA, PAI-1,
TIMP-1), as well as markers of hypoxia (CA IX). In addition to the new CA
IX IHC which is a class 1 IVD test, WILEX Inc. provides the only
FDA-cleared IVD ELISA that measures the serum HER-2/neu level for the
management and monitoring of patient care for women with metastatic breast
cancer. WILEX Inc. is based in Cambridge, MA, USA and also provides GMP and
ISO certified manufacturing services. More information is available on
www.oncogene.com.
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company develops diagnostic and therapeutic product
candidates for the specific detection and targeted treatment of various
types of cancer based on antibodies and small molecules. Beside the
manufacturing and marketing of the biomarker tests from WILEX Inc. the
subsidiary Heidelberg Pharma GmbH offers preclinical contract research
services and an antibody drug conjugate (ADC) technology platform. The
business model comprises research and product development as well as the
commercialisation of its activities. Our customers and partners include
leading international pharmaceutical companies. WILEX is listed at the
Frankfurt Stock Exchange. ISIN DE0006614720 / WKN 661472 / Symbol WL6. More
information is available on www.wilex.com.
Contact
WILEX AG
Corporate Communications
Katja Arnold (CIRO)
Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-Mail: investors(at)wilex.com
Immundiagnostik AG
Corporate Communication&Marketing
Dr. Susanne Kuhlendahl
Stubenwaldallee 8a
64625 Bensheim
Tel.: +49 6251 70190 36
Fax: +49 6251 849430
Email: susanne.kuhlendahl(at)immundiagnostik.com
This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.
End of Corporate News
---------------------------------------------------------------------
12.12.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info(at)wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
196705 12.12.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 12.12.2012 - 07:11 Uhr
Sprache: Deutsch
News-ID 211884
Anzahl Zeichen: 21733
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 255 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: WILEX AG: WILEX Inc. signs distribution agreement with Immundiagnostik AG for D-A-CH region"
steht unter der journalistisch-redaktionellen Verantwortung von
WILEX AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
